LifeMD Collaborates with Novo Nordisk to Launch $299 Introductory Bundle for Self-Pay Patients Prescribed Wegovy®
LifeMD (NASDAQ: LFMD) has partnered with Novo Nordisk to launch a limited-time $299 introductory bundle for self-pay patients prescribed Wegovy®. The bundle includes Wegovy® at $199 and LifeMD's virtual weight management program, available until June 30, 2025. After the first month, the program will cost $599 monthly with no long-term commitment required.
The collaboration strengthens LifeMD's ability to deliver FDA-approved GLP-1 medications through an integrated care experience, targeting patients seeking alternatives to compounded therapies. LifeMD's platform provides comprehensive services from virtual consultation to prescription fulfillment and ongoing support. Wegovy® is available through NovoCare® Pharmacy integration for eligible uninsured patients or those whose insurance doesn't cover weight-loss medications.
LifeMD (NASDAQ: LFMD) ha stretto una partnership con Novo Nordisk per lanciare un pacchetto introduttivo a tempo limitato di 299$ per i pazienti che pagano di tasca propria e a cui è stato prescritto Wegovy®. Il pacchetto include Wegovy® a 199$ e il programma virtuale di gestione del peso di LifeMD, disponibile fino al 30 giugno 2025. Dopo il primo mese, il programma costerà 599$ al mese senza obblighi a lungo termine.
La collaborazione rafforza la capacità di LifeMD di fornire farmaci GLP-1 approvati dalla FDA attraverso un'esperienza di cura integrata, rivolta ai pazienti che cercano alternative alle terapie composte. La piattaforma di LifeMD offre servizi completi dalla consulenza virtuale alla prescrizione e al supporto continuo. Wegovy® è disponibile tramite l'integrazione con la farmacia NovoCare® per pazienti non assicurati idonei o per chi ha una copertura assicurativa che non include farmaci per la perdita di peso.
LifeMD (NASDAQ: LFMD) se ha asociado con Novo Nordisk para lanzar un paquete introductorio por tiempo limitado de $299 para pacientes que pagan por su cuenta y han sido recetados con Wegovy®. El paquete incluye Wegovy® a $199 y el programa virtual de manejo de peso de LifeMD, disponible hasta el 30 de junio de 2025. Después del primer mes, el programa costará $599 mensuales sin compromiso a largo plazo.
La colaboración fortalece la capacidad de LifeMD para ofrecer medicamentos GLP-1 aprobados por la FDA a través de una experiencia de cuidado integrada, dirigida a pacientes que buscan alternativas a terapias compuestas. La plataforma de LifeMD proporciona servicios integrales desde la consulta virtual hasta la entrega de recetas y soporte continuo. Wegovy® está disponible mediante la integración con la farmacia NovoCare® para pacientes elegibles sin seguro o aquellos cuya cobertura no incluye medicamentos para la pérdida de peso.
LifeMD (NASDAQ: LFMD)는 Novo Nordisk와 협력하여 Wegovy® 처방을 받은 자비 부담 환자를 위한 한정 기간 $299 소개 패키지를 출시했습니다. 이 패키지에는 Wegovy®가 $199에 포함되며, LifeMD의 가상 체중 관리 프로그램이 2025년 6월 30일까지 제공됩니다. 첫 달 이후 프로그램 비용은 월 $599이며 장기 약정은 필요 없습니다.
이번 협력은 FDA 승인 GLP-1 약물을 통합된 케어 경험을 통해 제공하는 LifeMD의 역량을 강화하며, 복합 치료법을 대체하려는 환자들을 대상으로 합니다. LifeMD 플랫폼은 가상 상담부터 처방 이행 및 지속적인 지원까지 포괄적인 서비스를 제공합니다. Wegovy®는 보험이 없거나 체중 감량 약물 보장이 없는 대상 환자를 위해 NovoCare® 약국 통합을 통해 이용 가능합니다.
LifeMD (NASDAQ : LFMD) s'est associé à Novo Nordisk pour lancer une offre de lancement limitée à 299 $ destinée aux patients en paiement direct prescrits avec Wegovy®. Le forfait comprend Wegovy® à 199 $ ainsi que le programme virtuel de gestion du poids de LifeMD, disponible jusqu'au 30 juin 2025. Après le premier mois, le programme coûtera 599 $ par mois sans engagement à long terme.
Cette collaboration renforce la capacité de LifeMD à fournir des médicaments GLP-1 approuvés par la FDA via une expérience de soins intégrée, ciblant les patients recherchant des alternatives aux thérapies composées. La plateforme de LifeMD offre des services complets, de la consultation virtuelle à la délivrance de prescriptions et au soutien continu. Wegovy® est disponible grâce à l'intégration avec la pharmacie NovoCare® pour les patients non assurés éligibles ou ceux dont l'assurance ne couvre pas les médicaments amaigrissants.
LifeMD (NASDAQ: LFMD) hat eine Partnerschaft mit Novo Nordisk geschlossen, um ein zeitlich begrenztes Einführungsangebot für Selbstzahler in Höhe von 299 $ für Patienten, denen Wegovy® verschrieben wurde, anzubieten. Das Paket umfasst Wegovy® für 199 $ sowie das virtuelle Gewichtsmanagementprogramm von LifeMD, verfügbar bis zum 30. Juni 2025. Nach dem ersten Monat kostet das Programm 599 $ pro Monat ohne langfristige Bindung.
Die Zusammenarbeit stärkt LifeMDs Fähigkeit, von der FDA zugelassene GLP-1-Medikamente über ein integriertes Betreuungserlebnis bereitzustellen, das sich an Patienten richtet, die nach Alternativen zu zusammengesetzten Therapien suchen. Die Plattform von LifeMD bietet umfassende Dienstleistungen von der virtuellen Beratung bis zur Rezeptausstellung und fortlaufender Unterstützung. Wegovy® ist über die Integration der NovoCare®-Apotheke für berechtigte nicht versicherte Patienten oder solche, deren Versicherung keine Gewichtsverlustmedikamente abdeckt, erhältlich.
- Partnership with major pharmaceutical company Novo Nordisk enhances credibility and market position
- Competitive pricing strategy with $299 introductory bundle could drive customer acquisition
- Integration with NovoCare® Pharmacy streamlines prescription fulfillment process
- Expanded access to FDA-approved Wegovy® could increase revenue through recurring $599 monthly subscriptions
- No long-term commitment requirement reduces barrier to entry for new patients
- Significant price increase to $599 after first month might lead to high customer churn
- Limited-time offer ending June 30, 2025 may create pressure on operational capacity
- Focus on self-pay patients limits the addressable market
Insights
LifeMD's Novo Nordisk partnership creates a differentiated pricing model for GLP-1 access, potentially driving revenue growth and competitive advantage.
This collaboration between LifeMD and Novo Nordisk represents a strategic positioning in the rapidly expanding GLP-1 weight management market. By offering Wegovy at
The economics here are compelling. With a discounted acquisition cost in month one, LifeMD can likely achieve substantial patient conversion while maintaining healthy margins on the
From a business perspective, this represents a triple win: Novo Nordisk expands distribution of FDA-approved Wegovy (competing against compounded alternatives), LifeMD secures a potentially high-margin recurring revenue stream, and patients gain access to authenticated medications with integrated clinical support. The limited-time nature of the offer (ending June 30) creates urgency while the absence of long-term commitments reduces friction in patient acquisition.
This model leverages LifeMD's vertically integrated telehealth infrastructure—connecting their medical group, prescription capabilities, and ongoing coaching—creating a defensible competitive advantage in an increasingly crowded GLP-1 marketplace. By focusing on self-pay patients, they're targeting a segment with both higher margins and fewer administrative complexities than insurance-dependent models.
Bundled Offer Includes Wegovy® at
NEW YORK, May 22, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced a limited-time
The collaboration with Novo Nordisk strengthens LifeMD’s ability to deliver branded GLP-1 medications through a fully integrated care experience, addressing the needs of the growing number of self-pay patients seeking FDA-approved replacements for compounded therapies. LifeMD’s platform provides an end-to-end model—from virtual consultation to prescription fulfillment to ongoing coaching and support—ensuring continuity of care at every stage of the weight loss journey.
The
“Our collaboration with Novo Nordisk reflects LifeMD’s commitment to improving affordability, convenience, and access for patients seeking medically guided weight loss,” said Justin Schreiber, Chairman and CEO of LifeMD. “This bundled solution provides a seamless, affordable on-ramp to FDA-approved GLP-1 therapy—replacing the fragmented and often inconsistent experience many patients have faced with compounded alternatives. We look forward to expanding this collaboration to reach more patients and drive better outcomes at scale.”
“Novo Nordisk continues to work with LifeMD to expand access to authentic, FDA-approved Wegovy®, a proven therapy for chronic weight management along with a reduced calorie diet and increased physical activity,” said Dave Moore, Executive Vice President, US Operations of Novo Nordisk Inc. “This collaboration enables patients to begin their treatment journey through a trusted virtual care platform. We look forward to this collaboration and improving access and outcomes for patients nationwide.”
LifeMD’s weight management program delivers personalized, clinically guided care for patients across the U.S. By leveraging its vertically integrated platform—including a 50-state medical group and national diagnostic lab partnerships—LifeMD offers a seamless experience from consultation through prescription fulfillment and ongoing support. To learn more about LifeMD's
Wegovy® is the first GLP-1 therapy approved in the United States for both chronic weight management and cardiovascular risk reduction in adults with obesity. Through this offering, all doses of Wegovy® are available in an injector pen – by prescription – to eligible LifeMD patients who are uninsured or whose insurance does not cover prescription weight-loss medications.
About LifeMD, Inc.
LifeMD® is a leading provider of virtual primary care. LifeMD offers telemedicine, access to laboratory and pharmacy services, and specialized treatment across more than 200 conditions, including primary care, men’s and women’s health, weight management, and hormone therapy. The Company leverages a vertically integrated, proprietary digital care platform, a 50-state affiliated medical group, a 22,500-square-foot affiliated pharmacy, and a U.S.-based patient care center to increase access to high-quality and affordable care. For more information, please visit LifeMD.com.
Cautionary Note Regarding Forward Looking Statements
This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended; Section 21E of the Securities Exchange Act of 1934, as amended; and the safe harbor provision of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this news release may be identified by the use of words such as: “believe,” “expect,” “anticipate,” “project,” “should,” “plan,” “will,” “may,” “intend,” “estimate,” “predict,” “continue,” and “potential,” or, in each case, their negative or other variations or comparable terminology referencing future periods. Examples of forward-looking statements include, but are not limited to, statements regarding our financial outlook and guidance, short and long-term business performance and operations, future revenues and earnings, regulatory developments, legal events or outcomes, ability to comply with complex and evolving regulations, market conditions and trends, new or expanded products and offerings, growth strategies, underlying assumptions, and the effects of any of the foregoing on our future results of operations or financial condition.
Forward-looking statements are not historical facts and are not assurances of future performance. Rather, these statements are based on our current expectations, beliefs, and assumptions regarding future plans and strategies, projections, anticipated and unanticipated events and trends, the economy, and other future conditions, including the impact of any of the aforementioned on our future business. As forward-looking statements relate to the future, they are subject to inherent risk, uncertainties, and changes in circumstances and assumptions that are difficult to predict, including some of which are out of our control. Consequently, our actual results, performance, and financial condition may differ materially from those indicated in the forward-looking statements. These risks and uncertainties include, but are not limited to, “Risk Factors” identified in our filings with the Securities and Exchange Commission, including, but not limited to, our most recently filed Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and any amendments thereto. Even if our actual results, performance, or financial condition are consistent with forward-looking statements contained in such filings, they may not be indicative of our actual results, performance, or financial condition in subsequent periods.
Any forward-looking statement made in the news release is based on information currently available to us as of the date on which this release is made. We undertake no obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, except as may be required under applicable law or regulation.
Investor Contact:
Marc Benathen, Chief Financial Officer
marc@lifemd.com
Media Contact:
Jessica Friedeman, Chief Marketing Officer
press@lifemd.com
FAQ
What is included in LifeMD's $299 Wegovy bundle?
How much does LFMD's Wegovy program cost after the first month?
When does LifeMD's Wegovy introductory offer expire?
Who is eligible for LifeMD's Wegovy program?
What services does LifeMD provide in their weight management program?
